Urology Austin

Futó vizsgálatok

• Toboroz

  A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

  NCT07725796· 1. fázis· Forrás

• Toboroz

  WATER IV PCa (AS Sub-study)

  NCT07650448· Forrás

• Toboroz

  Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

  NCT07569926· 4. fázis· Forrás

• Toboroz

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· 3. fázis· Forrás

• Fut, nem toboroz

  PSMA PET Combined With MRI for the Detection of PCa

  NCT07052214· 3. fázis· Forrás

• Toboroz

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· 2. fázis· Forrás

• Fut, nem toboroz

  WATER IV Prostate Cancer

  NCT06651632· Forrás

• Toboroz

  Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial

  NCT06496256· Forrás

• Toboroz

  A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

  NCT06545955· 3. fázis· Forrás

• Toboroz

  Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06510374· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

  NCT06211764· 3. fázis· Forrás

• Fut, nem toboroz

  Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer

  NCT05683691· Forrás

• Fut, nem toboroz

  A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)

  NCT05714202· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

  NCT05316155· 1/2. fázis· Forrás

• Toboroz

  LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

  NCT04752722· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy

  NCT04640623· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

  NCT01436968· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Hólyagrák6 toboroz
• Prosztatarák3 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Lezárult

  A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX

  NCT05467176· Forrás